Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus

Table 1 Bariatric endoscopic procedure

Intraluminal devices

Intragastric balloon

Orberaa

ReShapea

Obalona

Duodeno-jejunal bypass sleeve (EndoBarrier)

Aspiration therapy (AspireAssist)

Intraluminal suturing

Endoscopic sleeve gastroplasty

Transoral gastroplasty

^aIn order of date approved by United States Food and Drug Administration.

Table 2 Long term weight loss after bariatric surgery

Ref.	Studya	Type of surgeryb	Follow up	Result (%)1
[52]	MA	AGB	≥ 10 yr	EWL: 47.4
[52]	MA	VSG	≥ 5 yr	EWL: 53.2
[52]	MA	RYGB	≥ 10 yr	EWL: 63.5
[44]	MCS	AGB	15 yr	MWL: 13.0
[44]	MCS	RYGB	15 yr	MWL: 27.0
[53]	SCS	VSG	8 yr	EWL: 67.0
[54]	SCS	VSG	8 yr	EWL: 51.1
[55]	MCS	VSG	10 yr	EWL: 70.5
[56]	SR	AGB	3-5 yr	EWL: 45.0
[56]	SR	VSG	3-5 yr	EWL: 64.5
[56]	SR	RYGB	3-5 yr	EWL: 65.7

^aMA: Meta-analysis; MCS: Multi-center study; SCS: Single-center study; SR: Systematic review;

^bAGB: Adjustable gastric band; VSG: Vertical sleeve gastrectomy; RYGB: Roux-en-Y gastric bypass;

¹EWL: Mean percentage excess weight loss; MWL: Mean weight loss.

Table 3 Long term control of diabetes mellitus after bariatric surgery

Ref.	Type of studya	Surgeryb	Follow up	Result1
[53]	SCS	VSG	8 yr	NoRMRxDM: 43.4%
[54]	SCS	VSG	8 yr	NoRMRxDM: 37%
[56]	SR	AGB	3-5 yr	NoRMRxDM: 28.6%
[56]	SR	RYGB	3-5 yr	NoRMRxDM: 66.7%
[57]	SCS	RYGB	9 yr	NoRMRxDM: 73%
[58]	MCS	AGB	15 yr	NoRMRxDM: 38%
[58]	MCS	RYGB	15 yr	NoRMRxDM: 35%
[62]	NPBCS	AGB	6 yr	NoRMRxDM: 32%
[62]	NPBCS	VSG	6 yr	NoRMRxDM: 41%
[62]	NPBCS	RYGB	6 yr	NoRMRxDM: 58%
[63]	SCS	AGB	10 yr	NoRMRxDM: 18%

^aSCS: Single-center study; SR: Systematic review; MCS: Multi-center study; NPBCS: Nationwide population-based cohort study;

^bAGB: Adjustable gastric band; VSG: Vertical sleeve gastrectomy; RYGB: Roux-en-Y gastric bypass;

¹NoRMRxDM: No requirement for medical therapy for diabetes mellitus.